From: Expression of the luteinizing hormone receptor (LHR) in ovarian cancer
Total Patients | 232 | 100% | |||
Surgery done | 08/02/91–12/13/12 | ||||
Age at Diagnosis | |||||
< 60 | 130 | 56% | |||
≥ 60 | 102 | 44% | |||
Median (Range) | 58 (26–89) | ||||
Tumor Histology | |||||
Serous Carcinoma | 160 | 69% | |||
Endometrioid Adenocarcinoma | 21 | 9% | |||
Clear Cell Carcinoma | 17 | 7% | |||
Mixed | 15 | 6% | |||
Mucinous Carcinoma | 13 | 6% | |||
MMMT | 4 | 2% | |||
Undifferentiated | 2 | 1% | |||
Pathologic Stage | |||||
I | 50 | 22% | |||
II | 18 | 8% | |||
III | 140 | 60% | |||
IV | 24 | 10% | |||
Silberberg’s Grade | |||||
1 | 27 | 12% | |||
2 | 28 | 12% | |||
3 | 177 | 76% | |||
Received Chemotherapy | |||||
No | 16 | 7% | |||
Yes | 216 | 93% | |||
Residual Disease | |||||
No | 113 | 49% | |||
Yes | 119 | 51% | |||
Persistent Disease | |||||
No | 144 | 62% | |||
Yes | 88 | 38% | |||
LHR-I | |||||
Negative | 30 | 13% | |||
Weak | 24 | 10% | |||
Moderate | 26 | 11% | |||
Strong | 152 | 66% | |||
LHR-P | |||||
0% | 30 | 13% | |||
1–50% | 4 | 2% | |||
> 50% | 197 | 85% | |||
Missing/LHR Intensity Negative | 1 | ||||
Tumor Histology | N | LHR Expression Intensity | |||
Negative | Weak | Moderate | Strong | ||
Serous Carcinoma | 160 | 16 (10%) | 19 (12%) | 16 (10%) | 109 (68%) |
Endometrioid Adenocarcinoma | 21 | 3 (14%) | 2 (10%) | 3 (14%) | 13 (62%) |
Clear Cell Carcinoma | 17 | 0 (0%) | 0 (0%) | 4 (24%) | 13 (76%) |
Mixed | 15 | 4 (27%) | 1 (7%) | 3 (20%) | 7 (47%) |
Mucinous Carcinoma | 13 | 6 (46%) | 2 (15%) | 0 (0%) | 5 (38%) |
MMMT | 4 | 1 (25%) | 0 (0%) | 0 (0%) | 3 (75%) |
Undifferentiated | 2 | 0 (0%) | 0 (0%) | 0 (0%) | 2 (100%) |